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COMMENTS
AN FDA-EEC PERSPECTIVE ON THE INTERNATIONAL
AccEPTANcE OF FOREIGN CLINICAL DATA
INTRODUCTION
When Beth and her husband spent the year in London, she found
relief from her asthma for the first time in years. Her British doctor
prescribed Zaditen (ketotifen), 1 a popular medication that has been
available in Europe for many years. When she returned to the U.S.,
however, Beth was disappointed to learn that Zaditen was not
available. In desperation, Beth had friends in England send it to her.
Bill was not so fortunate. He suffered from Parkinson's disease
and the medications his doctor had tried were no longer working
well. He knew another Parkinson's patient who was in good shape.
He was from Austria and his family was sending him Eldepryl
(deprenyl).2 It had been available in Europe since the early 1980s,
but it was not approved in the U.S. until 1989, by which time Bill's
condition had deteriorated considerably.
3
Unfortunately, there are many people like Beth and Bill, not only in the
United States but around the world, who can't get access to new drugs. Many
drugs, which are available in some countries, are not available in others because
drug regulatory agencies decide differently in approving or rejecting a new drug
for distribution to patients like Beth and Bill.
One of the most important factors a drug regulatory agency must consider in
making the decision to approve or reject a new drug is analyzing the data derived
from clinical tests on humans which shows if a new drug is safe and effective.
Drug regulatory agencies are exacting in their scrutiny of this clinical data4
because it often determines if a new drug will be approved or rejected for
distribution.
1. Zaditen (ketotifen) is used in the prophylactic treatment of asthma and has also been given
in the treatment of allergic conditions such as rhinitis and conjunctivitis.
2. Eldepryl (deprenyl) enhances the effects of levodopa and is used in Parkinson's disease as
an adjunct to levodopa therapy, usually when fluctuations in mobility have become a problem. It has
also been tried in the treatment of depression.
3. San Diego Tribune, Aug. 24, 1990, at D2, col. 3.
4. Clinical data refers to data derived from any experiment in which a drug is administered
to, or used involving, one or more human subjects.
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If this clinical data is derived from a foreign source, then the drug regulatory
agency treats it even more critically because the data is more difficult to verify
and validate. Regulatory authorities often accept a filing but find the foreign
clinical data methodologically insufficient, and require the sponsor5 to re-
perform the clinical trials under domestically sanctioned methods at domestic
clinical sites. This results in added expense and delay in receiving approval to
distribute a new drug.
The purpose of this Comment is to analyze the problems associated with the
international acceptance of foreign clinical data, address the current regulations
which determine when such data is acceptable, and introduce solutions which will
facilitate the pharmaceutical industry in achieving its goal of distributing life
saving drugs to patients like Beth and Bill. With this goal of improved health
care in mind, this Comment focuses upon two drug regulatory agencies which
have recently addressed the subject: the Food and Drug Administration ("FDA")
in the United States and the Committee for Proprietary Medicinal Products
("CPMP") in the European Economic Community ("EEC").6
First, the background of this controversy is discussed, including some of the
problems which inhibit the acceptance of foreign clinical data. Second, FDA
policy is assessed with particular attention placed upon the difficulties of non-
U.S. clinical investigators meeting FDA requirements such as ethical review,
patient informed consent, adherence to the protocol, and general record keeping.
Third, the EEC standard for accepting foreign clinical data is analyzed, including
a discussion of the various interpretations which have resulted from this
standard, as well as a discussion of the steps which have been taken to reduce
these varied interpretations. Finally, the barriers inhibiting the international
acceptance of foreign clinical data are discussed and specific solutions are
proposed to reduce these barriers. These solutions include increasing the
methods of communication between regulatory agencies through memorandums
of understanding, contract research organizations, and internationalizing
assessment reports. Other solutions include reducing economic and political
forces and assembling an international drug dossier.
I. STATEMENT OF THE CONTROVERSY
The pharmaceutical industry has become one of the most regulated industries
in the world over the past decade because of its potential to affect such an
extraordinary number of people.7 On the one hand, expansive regulatory
5. "Sponsor' means a person who takes responsibility for and initiates a clinical investigation.
The sponsor may be an individual or pharmaceutical company, governmental agency, academic
institution, private organization, or other organization .. " 21 C.F.R. § 312.3(b) (1990).
6. The EEC is currently comprised of the following Member States: Belgium, Denmark,
France, Greece, Italy, Luxembourg, the Netherlands, Portugal, Spain, the United Kingdom, and
Germany.
7. See generally Comment, International Trends in New DrugApproval Regulation: The Impact
on Pharmaceutical Innovation, 10 RurGERS COMP. & TECH. LJ. 317, 318-19 (1984).
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controls have increased the quality of pharmaceutical drugs reaching the
marketplace. On the other hand, however, this increased regulation has caused
several problems for the pharmaceutical industry. One of the most troublesome
problems which accompanies this increased regulation is "the drug lag"8 which
delays the availability of new drugs to consumers.9
Drug regulatory agencies have recognized the problems associated with the
drug lag and have attempted to reduce these delays.'0 In doing so, these
agencies have recently focused on the acceptance of foreign clinical data." The
acceptance of foreign clinical data is important because it involves communica-
tion between drug regulatory agencies on an international scale; and "the issue
of the communication of drug information is critical because it relates to the
very basis of the value of pharmacotherapy in health care: the effective use of
drugs depends on the accurate and comprehensive communication and
understanding of information about them."'2
Various drug regulatory agencies have contrasting policies regarding the
acceptance of foreign clinical data to support a new drug application or
"registration." 3 Typically, the quality of the foreign clinical data is the most
important concern for these regulatory agencies because the agency can not
easily verify or validate the data since it was performed in a foreign country.
While the quality of the foreign clinical data is certainly a valid concern,
acceptance of this data by regulatory authorities is often conditioned on
"nationalism" rather than on medical comparability or dissimilarity. 14 National-
8. Cooper, The DrugLag, 37 FOOD DRUG COSM. LJ. 49,50 (1982); Dunning, Regulation, New
Drug Development, and the Question of Delay, 41 FOOD DRUG COSM. LJ. 139 (1986).
9. Kaitin, Mattison, Northington & Lasagna, The Drug Lag: An Update on New Drug
Introductions in the United States and in the United Kingdom, 1977 Through 1987, 46 CLIN.
PHARMACOL & THER. 121, 133-34 (1989).
During the 11-year period from 1977 through 1987, the United States not only lagged
behind the United Kingdom in the availability of new medications in each therapeutic
category, but it also had only one third the number of first introductions of mutually
available drugs and 23% fewer exclusively available drugs .... [Kaitin previously]
showed that of 46 new chemical entities approved by the FDA in 1985 and 1986, 33
(71.7%) had been marketed in foreign countries a mean of 5.5 years before U.S.
approval. Twelve of the 46 new chemical entities had been marketed 6 or more years
before U.S. approval. Although one would not expect any country to approve all new
drugs first, one would assume that a country such as the United States would not be
far down the list a majority of the time.
Id
10. See generally Poggiolini, International Regulation of Drugs, 22 DRUG INFO. J. 133 (1988);
Note, International Regulation of Pharmaceuticals: The Role of the World Health Organization, 23 VA.
J. INT'L. L. 331 (1983); Note, International Regulation of Pharmaceuticals: A WHO International Code
of Conduct for the Marketing of Phannaceuticals?, 11 SYRACUsE J. INT'L L. & CoM. 121 (1984).
11. O'Reilly, Three Dimensions of Regulatory Problems: United States, European Economic
Community, and National Laws, 41 FOOD DRUG COSM. LJ. 131, 132 (1986).
12. Hoff, The Role of the Innovation-Based Pharmaceutical Industy In International Drug
Information Communication, 17 DRUG INFO. J. 271 (1983).
13. Generally, only the FDA terms the new drug submission documents to be an "application."
International product submissions are generally termed "new drug registrations."
14. O'Reilly, supra note 11, at 132.
1991]
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ism can be briefly described as one agency's prejudice against another agency's
standard for accepting such data.'5  These "excuses" for rejecting foreign data
almost always require that repetitive testing be performed domestically so the
agency can more closely monitor the study and more easily validate the data.
t6
The effects of repetitive testing can be disastrous in terms of wasted time,
money and resources. For instance, finding a foreign testing facility capable of
adequately performing the clinical trial is difficult. 17 Additionally, data must be
re-prepared and re-organized to support the new drug registration. There is also
no guarantee that the data will be considered if a minor or technical mistake was
made along the way. Thus, an agency's refusal to accept foreign clinical data,
and the subsequent repetitive testing, magnifies the drug lag problem rather than
reduces it.
The FDA and CPMP have responded to the problems associated with the
international acceptance of foreign clinical data by passing regulations designed
to set standards in determining when the data will be acceptable. An examina-
tion of these standards is necessary in order to understand the barriers which
inhibit, and the solutions to encourage, the acceptance of foreign clinical data.
II. FDA POLICY
A. Prominence of the FDA in International Pharmaceutical Regulation
The FDA is the sole national food and drug regulatory agency in the United
States. Its authority is derived from the Federal Food Drug and Cosmetic
Act.' 8 The FDA has long been considered the most prominent drug regulatory
agency in the world and has established its position of leadership and prestige
in the community of international drug regulatory authorities.' 9
15. See infra notes 167-74 and accompanying text.
16. O'Reilly, supra note 11, at 132.
17. See infra notes 97-102 and accompanying text.
18. 21 U.S.C. §§ 301,321,331-337,341-469,347,348,351-353,355-357, 361-363,371-376,381,
391, 392 (1990). The original Act was passed in 1906 and has been amended numerous times to
clarify the requirements in assuring safe and effective performance of a new drug or medical device.
19. Halperin, Multinational and International Regulation of Pharmaceuticals and US. Policy,
17 DRUG INFO. J. 153, 154 (1983).
This reputation derives from several facts: 1) The agency is the largest drug regulatory
body in the world; it has the broadest [range] of statutes, regulations, guidelines, and
formal policies and procedures of any drug regulatory agency .... 2) A decision to
approve a drug for marketing in the United States-with its population of almost 230
million people-is possibly the single most important action affecting that drug
throughout its lifetime because it permits entry into the largest single market in the
world. It is a decision virtually equal to approving a drug for a population almost as
large as the entire [EEC]. 3) The American democratic system of government places
a high value on 'Government in the Sunshine.' . . . It is the most public system of
decision making in the world and the amount of information that is available to outside
parties for independent review of how the [FDA] exercises its statutory mandate is
more extensive than in other countries. 4) Finally, the agency itself takes its
responsibilities to the international community seriously and works hard to meet its
4
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Along with this prestige, the FDA must keep up to date with technological
advancements. The FDA's acceptance of foreign clinical data can be considered
a technological advancement because only recently has the international
community used foreign clinical data to support safety and efficacy of a new
drug. The FDA's awareness of the need to accept foreign clinical data can be
largely attributed to the pressure which private industry has placed upon the
FDA20
B. History of Accepting Foreign Clinical Data
The FDA advised the pharmaceutical industry in 1962 that foreign clinical data
meeting the standards of adequate and well-controlled studies would be
acceptable. 2' However, the FDA limited the use of this data to that of a
literature review," which meant that the data could only be used as supplemen-
tal information of the drug's safety and efficacy.
It was not until 1975 that the FDA accepted foreign clinical studies as primary
evidence of a drug's safety or efficacy.23 But even at this time, before the FDA
would accept the foreign clinical data, the drug in question must have been for
a major health gain, an uncommon disease, or must have had a strikingly
favorable benefit/risk ratio.24
Certainly the FDA's position has continued to evolve over the years
to one of greater acceptance and reliance on foreign studies. In part,
this probably reflects some evolution in the design and conduct of
clinical studies throughout the world, and the submission of higher
quality clinical data. As scientific standards for the clinical study of
drugs gain wider acceptance throughout the world, unnecessary
duplication of clinical studies becomes more clearly unjustifiable.25
commitments and maintain our reputation.
Id
20. Lisook & Sloboda, Food and Drug Administration Audit of Foreign Clinical Trials, 23
PSYCHOPHARMACOLOGY BULL. 193 (1987).
21. Bilstad, Foreign Clinical Data: FDA Perspective, Paper presented to the Fifth International
Meeting of Pharmaceutical Physicians, Munich, Federal Republic of Germany (Oct. 1984) (available
from Dr. Bilstad, Dept. of Health and Human Services, HFD-500, Public Health Service, Food and
Drug Administration, Rockville, MD, 20857).
22. Lisook & Sloboda, supra note 20 (citing Weintraub, Foreign Data: 1986 Status, Paper
presented to the 10th Annual Meeting of the Associates of Clinical Pharmacology, San Francisco, Cal.
(Apr. 1986)).
23. Lisook, FDA Investigation of Clinical Studies: Policy and Procedure, Paper presented at the
Third Annual European Symposium, Good Clinical Practice in Europe, Copenhagen, Denmark, at
14 (Mar. 3, 1989) (Dr. Lisook, who generously provided this article, is currently Chief of the Clinical
Investigations Branch, Division of Scientific Investigations, HFD-344, Office of Compliance, Center
for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 20857).
24. Id at 15.
25. Bilstad, supra note 21, at 1.
1991]
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Finally, in 1984, under pressure from foreign governments, pharmaceutical
companies, and academic and consumer groups, the FDA formally restated its
policy towards accepting foreign clinical data.
C. Current Policy
The FDA has recognized two categories concerning the acceptability of foreign
clinical data. These categories, discussed in more detail below, are: 1) foreign
clinical studies not conducted under an investigational new drug application
2 7
("IND"), and 2) marketing approval based solely on foreign clinical data. Once
these regulations have been presented, a brief comparison of their applicability
is discussed.
1. Foreign Clinical Studies Not Conducted Under an IND.' In general, FDA
accepts foreign clinical studies not conducted under an IND if the studies are
"well designed, well conducted, performed by qualified investigators,' and
conducted in accordance with ethical principles acceptable to the world
community."29 Studies meeting these criteria may be used to support clinical
investigations30 and/or marketing approval in the United States.31 A sponsor
who wishes to rely on foreign clinical studies to support an IND 32 or to support
a new drug application ("NDA")33 must submit the following information to the
FDA:m
(1) A description of the investigator's qualifications;
(2) A description of the research facilities;
(3) A detailed summary of the protocol and results of the study, and,
should FDA request, case records maintained by the investigator or
26. Lisook & Sloboda, supra note 20, at 193.
27. An investigational new drug exemption refers to a scientific document submitted to and
reviewed by the FDA. The new drug is one which the FDA has not yet approved for marketing
distribution and can only be placed in interstate commerce for the purpose of scientific investigation.
Investigational new drug is defined as "a new drug, antibiotic drug, or biological drug that is used in
a clinical investigation. The terms also includes a biological product that is used in vitro for
diagnostic purposes." 21 C.F.R. § 312.3(b) (1990).
28. 'Investigator' means an individual who actually conducts a clinical investigation (i.e., under
whose immediate direction the drug is administered or dispensed to a subject) .. " 21 C.F.R. §
312.3(b) (1990).
29. 21 C.F.R. § 312.120(a) (1990).
30. "'Clinical investigation' means any experiment in which a drug is administered or dispensed
to, or used involving, one or more human subjects." 21 C.F.R. § 312.3(b) (1990).
31. 21 C.F.R. § 312.120(a) (1990).
32. For the IND regulations, see 21 C.F.R. § 312 (1990). Part 312 describes the general
provisions governing the IND application (§§ 312.1-312.10), the IND application procedure (§§
312.20-312.28), administrative actions (§§ 312.40-312.48), responsibilities of sponsors and investigators
(§§ 312.50-312.70), drugs intended to treat life-threatening and severely-debilitating illnesses (§§
312.80-312.88), miscellaneous provisions (§§ 312.110-312.145).
33. FDA has codified the new drug application procedure at 21 C.F.R. § 314 (1990).
34. 21 C.F.R. § 312.120(b) (1990).
6
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additional background data such as hospital or other institutional
records;
(4) A description of the drug substance and drug product used in the
study, including a description of components, formulation, specifica-
tions and bioavailability of the specific drug product used in the
clinical study, if available; and
(5) If the study is intended to support the effectiveness of a drug
product, information showing that the study is adequate and well
controlled under § 314.126."
Furthermore, the sponsor must conform with ethical principles as stated in the
Declaration of Helsinki.36 The FDA has adopted certain provisions of the
Declaration because it is considered the most modern international instrument
in dealing with medical research.37
2. Marketing Approval Based Solely on Foreign Clinical Data. The FDA has
also promulgated standards under which foreign clinical data can be used as the
sole basis for marketing approval? 8 A new drug based solely on foreign clinical
data may be approved if:
(1) The foreign clinical data are applicable to U.S. population and
U.S. medical practice;
(2) The studies have been performed by clinical investigators of
recognized competence; and
(3) The data may be considered valid without the need for an on-site
inspection by FDA or, if FDA considers such an inspection to be
necessary, FDA is able to validate the data through an on-site
inspection or other appropriate means.39
If an application fails to meet any of these criteria, it will not be approved on
35. 21 C.F.R. § 312.120(b) (1990).
36. 21 C.F.R. § 312.120(c) (1990). Such an example of an ethical principle is found in the
Declaration of Helsinki § 111(4) which states that "[i]n research on man, the interest of science and
society should never take precedence over considerations related to the well-being of the subject,"
reprinted in 21 C.F.R. § 312.120(c)(4) (1990).
37. Deutsch, Medical Erperimentation: International Rules and Practice, 19 VICT. U. WELL.
L.R. 1, 7 (1990).
[The Declaration] is universally accepted because it makes the necessary distinction
between therapeutic research and purely scientific experimentation; it insists on a
medically acceptable benefit-risk ratio; it requires the informed consent of the subject;
it installs ethical committees, and finally it requires publishers of learned journals to
assess the ethical propriety of medical research papers submitted.
Id
38. 21 C.F.R. § 314.106 (1990).
39. Id.
19911
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the foreign clinical data alone.40 However, the FDA is flexible and encourages
applicants to meet with agency officials in a "presubmission" meeting when
approval is based solely on foreign clinical data.4t
The three criteria listed immediately above are only relevant if a foreign
clinical trial is pivotal for FDA approval (for example, one of only two clinical
trials showing effectiveness). 2 If U.S. data exists which is convincing per se,
and foreign trials confirm the U.S. data, then FDA is not overly concerned about
the foreign data. 43 In other words, the acceptance of foreign trials as evidence
of a drug's effectiveness is primarily a problem where the data is essential for
U.S. approval.44
3. Comparing the FDA Standards. The FDA's policy in accepting foreign
clinical data is not affected by the regulation under which the sponsor decides
to submit the data.45 In both of the aforementioned regulations, the FDA
typically treats the foreign clinical data the same.46 The reason there are
different sets of regulations is because the foreign data will be assessed at
different times during the application process. For example, if an IND
application is not held up by the FDA, the sponsor is authorized to perform
clinical trials involving the new drug.47 However, the sponsor must still follow
the NDA procedure before the drug will be approved for marketing distribu-
tion.48 This NDA must include any data which the FDA originally assessed in
granting the IND application to the sponsor. As a result, the FDA can track the
history of the drug through the application process and can determine if and
when the foreign clinical data was originally assessed.
Additionally, there is one unstated difference that the FDA applies between
the regulations. When the FDA receives an application involving foreign data,
they often conduct an investigation of the location where the data was derived.49
The FDA usually classifies these either as "routine" investigations or "for-cause"
investigations. 0 The routine investigation does not require participation by
FDA headquarters staff personnel at the study site, and is generally accomplished
40. Id
41. Id
42. Lasagna, On Reducing Waste in Foreign Clinical Trials and Postregulation Erperience, 40
CLIN. PHARMACOL. & THER. 369, 370 (1986).
43. Id.
44. Id.
45. Telephone interview with Dr. Alan Lisook, Chief of the Clinical Investigations Branch,
Division of Scientific Investigations, Office of Compliance, Center for Drug Evaluation & Research,
Food and Drug Administration (Sept. 11, 1990).
46. Id.
47. See supra notes 27-35 and accompanying text.
48. See supra note 33 and accompanying text.
49. See Lisook, supra note 23. See also P. Smith, FDA's International Regulatory Role
Through the Foreign Inspection Program (Sept. 1990) (available from Arthur A. Checchi, Inc., (292)
452-8666, Document I.D. No. 001-0133).
50. Telephone interview, supra note 45. See also Lisook, supra note 23.
8
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with an FDA field investigator and the clinical investigator, not the sponsor.51
A for-cause investigation generally involves an FDA investigator and the
participation of a member of FDA headquarters staff at the study site.52  The
FDA usually classifies foreign studies as for-cause investigations only because the
foreign data is pivotal for FDA approval. 3 The important aspect to keep in
mind is that, by following the regulatory requirements outlined above, a sponsor
can reduce the delays associated with receiving FDA approval.
4. Examples of Approved Drugs Based Upon Foreign Clinical Data. Only
recently and in rare circumstances has FDA granted approval for new drugs
based upon foreign clinical data. "The timolo1 54 clinical study conducted in
Norway was a historic first, the first drug accepted by FDA on the basis of solely
non-U.S. clinical testing."55 Besides timolol, only three other drugs based solely
on non-U.S. clinical studies have been approved by the FDA: Mesnex,5 6 Haldol
51. Telephone interview, supra note 45. Under the routine inspection program, approximately
200-250 inspections of clinical investigations per year are performed in the drug area. The inspections
are limited in scope and are conducted by members of an FDA field staff. The assignments are
issued as needed and are based almost exclusively on studies which are deemed important to the
evaluation of new drug applications pending before the agency. With certain exceptions, important
studies in every NDA which contains clinical data are the subject of such inspections. Lisook, supra
note 23, at 3.
52. Telephone interview, supra note 45. The reasons for the initiation of such "for-cause"
inspections are diverse. Although they are termed "for-cause" inspections, this does not necessarily
mean that information exists which would lead one to believe that work was done improperly. An
inspection of a clinical investigator may be initiated because: 1) they are doing a large volume of
work; 2) they have done work outside their field of specialty; 3) they report efficacy for a drug which
appears to be too good when compared with the results of other physicians studying the same drug;
4) they report no toxicity or few adverse reactions when other physicians report numerous adverse
reactions; 5) they seem to have too many patients with a given disease for the locale where they
practice; 6) they report laboratory results which are consistent beyond usual biologic variation or
which are inconsistent with results submitted by other investigators; 7) representatives of the sponsor
have reported that they are having difficulty getting case reports from the investigator, 8) a subject
of a study complains to FDA about violations of the protocol or the patient's rights; 9) they have
done a truly pivotal piece of work which merits in-depth examination because of its importance. This
includes all foreign studies which are primary evidence in support of U.S. drug approval; 10) they have
done a study which draws significant media attention. Lisook, supra note 23, at 8-9 (emphasis added).
53. Telephone interview, supra note 45. Once it has been determined that a "for-cause"
inspection is to take place, arrangements are made with the clinical investigator. Procedures used are
essentially the same as in the routine inspections, except that the data audit goes into greater depth,
covers a larger number of individual case reports, and may, as indicated, cover more than one study.
If deficiencies are found which indicate that the investigator has repeatedly or deliberately violated
FDA regulations, or has submitted false information to the sponsor in a required report, then FDA
will initiate actions which may ultimately result in the determination that the clinical investigator not
receive investigational new drugs in the future. Lisook, supra note 23, at 10. See also O'Reilly, More
Gold and More Fleece: Improving the Legal Sanctions Against Medical Research Fraud, 42 ADMIN. L.
REv. 393 (1990).
54. Timolol has been shown to be effective in preventing myocardial re-infarction. It has also
been effective in lowering intraocular pressure and may be indicated in patients with chronic open-
angle glaucoma or glaucoma in aphakic eyes.
55. O'Reilly, supra note 11, at 132 n.7.
56. Mesnex has been shown to be effective as a prophylactic agent in reducing the incidence
of ifosfamide induced hemorrhagic cystitis.
19911
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depot,57 and Cyclokapron.58
Other drugs where foreign clinical data has been pivotal in achieving FDA
approval are cimetidine, 9 nifedipine for vasospastic angina, 6 several oncolog-
ic6t drugs, and a radio-pharmaceutical 6 drug.6 Examples of new drugs
approved based on a combination of U.S. and non-U.S. studies include
Marinol," Buspar,6 Nolvadex," Losec, 67 and Nimotop.6
An example of where a United Kingdom license was granted entirely on the
basis of clinical data generated outside the U.K. is Azidothymidine ("AZT"). 69
The license was granted entirely on the basis of clinical data from the U.S.
70
Hopefully, such grants of approval based solely on foreign clinical data will
occur more frequently so that new drugs can reach patients sooner. The fact
that some drugs have been approved in the U.S. with the use of foreign clinical
data suggests that FDA is pushing toward this goal. However, for FDA to
accept future foreign clinical studies, private industry must be aware of certain
difficulties in meeting FDA requirements so that repetitive clinical trials can be
avoided.
57. Haldol (haloperidol) is indicated for use in the management of manifestations of psychotic
disorders. It is also indicated for the control of tics and vocal utterances of Tourette's disorder in
children and adults.
58. Cyclokapron (Tranexamic acid) is indicated for the management of hemophilic patients
undergoing tooth extraction or other oral surgical procedures.
59. Cimetidine inhibits gastric secretion of hydrochloric acid by all stimuli and is a frequently
used medication for the treatment of peptic ulcers.
60. Nifedipine (Procardia) is indicated for the management of vasospastic angina. It regularly
reduces arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and
reducing the total peripheral resistance against which the heart works. This unloading of the heart
reduces myocardial energy consumption and oxygen requirements.
61. Oncologic drugs help in the destruction of tumors in human patients.
62. A diagnostic radiopharmaceutical drug is one which is tagged with a radionuclide so that
is course can be traced, measured, or imaged.
63. Lasagna, supra note 42, at 369.
64. Marinol is indicated for the treatment of the nausea and vomiting associated with cancer
chemotherapy in patients who have failed to respond adequately to conventional antiemetic
treatments.
65. Buspar (Buspirone HCL) is an axiolytic which is indicated for the treatment of anxiety
disorders. Buspar is clinically effective for the management of anxiety disorders or the short-term
relief of symptoms of anxiety.
66. Nolvadex is effective in the treatment of metastatic breast cancer in women.
67. Losec (Omeprazole) is a drug which decreases gastric acid production; it is used in the
treatment of Zollinger-Ellison syndrome and in gastro-esophageal reflex disease.
68. Nimotop is indicated for the improvement of neurological deficits due to spasm following
subarachnoid hemorrhage from ruptured congenital intracranial aneurysms in patients who are in
good neurological condition post-ictus.
69. AZT (Azidothymidine or Zidovudine) is indicated as a primary agent in the treatment of
selected patients with symptomatic acquired immunodeficiency syndrome ("AIDS"). Zidovudine is
not a cure for AIDS.
70. Jones, Acceptance of Foreign Clinical Data, 22 DRUG INFO. J. 95, 96 (1988).
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D. Difficulties in Meeting FDA Requirements
A sponsor, when proffering foreign clinical data to the FDA, must be aware
of certain difficulties in meeting the regulatory requirements. These difficulties
most often arise in the areas of: 1) ethical review, 2) patient informed consent,3) adherence to the protocol, and 4) access to clinical records for inspection
purposes." These four categories are called difficulties because they can oftenbe the reason an FDA official decides to reject a particular foreign study.
Pcrcenlages
100
'75
Consent Protocol Records
ER
I thicti Review
206 inpections 9/88 9/89
2261 inspections 6/77 - 9/89
71. See generally Honohan, Practical Problems in the Conduct of Non-US Studies from WhichData Will Be Used for US Registration, 22 DRUG INFO. J. 193 (1988); Lisook, supra note 23.
Time Periods
6/77 - 9/8 E 9/ -9/9
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The FDA recently has tabulated data about the most common deficiencies
found in domestic studies. 72 The preceding graph shows that from June 1977 to
September 1989 the FDA conducted more than 2,000 investigations in the drug
area. Of these investigations, the graph shows the most common problems
associated with the performance of these studies. 73
1. Ethical Review. The Declaration of Helsinki74 requires that an ethical
review committee 7 must examine a sponsor's procedures before undertaking a
clinical trial. This requirement poses a problem if a committee is not available
at the study site for an independent review. In such a case, the sponsor must
demand that some type of ethical review be made available before the study
begins. For example, a "for profit" committee can be used to review the protocol
and maintain review of the study, or the sponsor can assist in the formulation
of an ethical review committee to review the protocol.76 At a minimum, FDA
requires that the sponsor submit the names and qualifications of the committee's
members77 in order to determine that a review committee in fact existed.
2. Patient Informed Consent. The investigator has the responsibility of
72. Lisook, supra note 23. For another recent study, see Food and Drug Administration, New
Molecular Entities Submitted in 1984-85: Analysis of Review Cycles, Amendments and Deficiencies
(Dec. 1988) (Evaluation and Analysis Staff, Office of Planning and Evaluation, Food and Drug
Administration, Rockville, MD, 20857).
73. Lisook, supra note 23, at 5-6 and figure 2. The graph requires some explanation. Since
an investigation may find multiple deficiencies or no deficiencies, the total percentages noted will not
equal 100. The 52% on problems with patient informed consent is not surprising since this figure
encompasses all instances where it was deemed necessary to make some comment to the investigator
concerning things which he included in the consent form which should not have been included, or
where something which should have been included was not. It was only the rare instance where
required consent was not obtained. The deviations from protoco the records' inaccuracy and records'
non-availability are of more concern. These are the figures which cast doubt upon the validity of the
studies audited It is this kind of problem which may cause the FDA to take a closer look at the clinical
investigator. Id. (emphasis added).
74. The Declaration of Helsinki, § 1(2), requires that "[t]he design and performance of each
experimental procedure involving human subjects should be clearly formulated in an experimental
protocol which should be transmitted to a specially appointed independent committee for
consideration, comment and guidance," reprinted in 21 C.F.R. § 312.120(c)(4) (1990).
75. An ethical review committee is an independent body whose responsibility is to verify that
the rights and integrity of humans in a particular study are protected, thereby providing public
assurances. The requirement that an ethical review committee exist to review the investigators
procedures and practices can be explained as follows:
Most scientists are under great pressure to conduct research and publish it. Publication
is the sole route to professional success, to salary increases, to tenure, to promotion.
Scientists, therefore, regard the terms and conditions of publication as matters of
considerable importance. There is no question that ethical review as a gate to
publication is an effective means of maintaining ethical standards in research. It is also
the most feasible method.
R. LEVINE, ETHics AND REGULATION OF CLINICAL RESEARCH 19 (1981).
76. Honohan, supra note 71, at 194.
77. 21 C.F.R. § 312.120(c)(3) (1990).
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obtaining written and signed patient informed consent 7s before the clinical study
begins.79 When a particular country or institution does not regularly require
signed patient consent forms, such assurances should be agreed upon between
the sponsor and the investigator before the study begins.8s
Two other alternatives can be used to satisfy the patient informed consent
requirement. A witness attestation form can be used where a witness signs the
consent form attesting to the fact that the patient was accurately informed.81
In the alternative, the investigator can sign a witness attestation form confirming
the fact that the patient received adequate information about the testing
involved.82 However, these methods are questionable when seeking FDA
approval because FDA requires patient informed consent to be in writing.
Therefore, if signed patient informed consent is not obtained, it is possible that
FDA may reject the entire study because there is no documentation that the
patient was adequately informed of the risks involved in participating in the
experiment, as required by the Declaration of Helsinki.
3. Protocol Non-Adherence. One of the most commonly encountered
circumstances which leads FDA to recommend the rejection of a particular
foreign study is the failure of the investigator to follow the protocol.83 There
are numerous way that an investigator can deviate from the protocol which
causes the FDA to be concerned. For example, misreporting the duration of
drug therapy and/or drug dosage; misreporting duration of disease remission by
using dates of office visits rather than reoccurrence of symptomology which
might have been weeks earlier; using ineligible subjects such as those with
minimal disease, undocumented disease, or with the wrong disease; and, finally,
the study may not have been double-blind as was required., 4
Such deviations from protocol are of great concern to the FDA when
78. The following dialogue serves as an example of the principle of patient informed consent:
Investigator (I): "Before we treat Mr. Jones with investigational drug X, we tell him
that drugs Y and Z are also likely to be effective for his condition." (Judgment).
Colleague (C): "Why should we tell him that?"
I: "Because the regulations state that we may not proceed without informed consent,
of which one essential component is a disclosure of any appropriate alternative
procedures that might be advantageous." (Rule).
C: "Why was that rule promulgated?"
I: "It is designed to be responsive to the principle of respect for persons, which requires
that we treat individuals as autonomous agents. Persons cannot be fully autonomous
without an awareness of the full range of options available to them." (Principle).
R. LEVINE, supra note 75, at 9.
79. Declaration of Helsinki § t(9), reprinted in 21 C.F.R. § 312.120(c)(4) (1990).
80. Honohan, supra note 71, at 194.
81. Id.
82. Id.
83. Lisook, supra note 23, at 18.
84. Id
1991]
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reviewing the practices of the investigator.85 These deviations, when they occur,
cast doubt on the validity of the studies audited.86 It is this kind of problem
that may cause FDA to reject a study as invalid and which may cause FDA to
look more closely at the clinical investigator.87 Therefore, it is of paramount
importance to follow the protocol as designed, or, in the alternative, to obtain
the proper approval by the ethical review committee and the consent of the
patient before deviating from the protocol.
4. Access to Clinical Records. Before the FDA will accept foreign clinical data,
they must be granted the opportunity to audit the study records. 8 This can be
a problem because some countries have legal restrictions denying access to
medical records.89 The laws are designed to keep patient information confiden-
tial."
Before the clinical study begins, an agreement must be made which would
allow FDA access to clinical records. A common practice is to have the auditor
sit with his case report forms on one side of a table, and the investigator with
the patient records on the other.9 This enables the investigator to immediately
answer any questions the auditor might pose.92 This approach, however, even
though acceptable by some regulatory agencies, is not acceptable to FDA. FDA
must have access to the patient records.93 The sponsor must therefore inquire
into any such legal restrictions before undertaking the study.
In sum, by taking these problems into consideration before foreign clinical
trials are initiated, the sponsor can assure FDA officials that the protocol was
strictly adhered to and that regulatory requirements have been met. When a
sponsor conducts a foreign clinical trial and submits the data to the FDA, the
FDA must be satisfied that an ethical review board existed, that the patients
were adequately informed, that the protocol was accurately followed, and that
clinical records are accurate and are available for inspection. If FDA finds that
these components exist, they are more inclined to accept the data because it has
met the regulatory requirements.
85. IdM at 6.
86. Id
87. Id When an FDA investigator discovers such a problem as a deviation from protocol, two
courses of action are open. The first is an expanded inspection covering the study which is currently
being audited. This is accomplished by sending additional case reports to the field. The second
course of action is to complete the inspection on the basis of the case reports already reviewed and
to initiate a "for cause" inspection in the near future to cover additional cases from the same study
as well as other studies which the clinical investigator has recently completed. See supra notes 49-53
and accompanying text. Lisook, supra note 23, at 6-7.
88. 21 C.F.R. § 314.106 (1990).
89. Honohan, supra note 71, at 195.
90. Id
91. Id at 196.
92. Id.
93. Telephone interview, supra note 45.
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E. Alternative Means of Qualifying Foreign Clinical Data
The FDA recognizes two other methods of facilitating the acceptability of
foreign clinical data. These are Memorandums of Understanding ("MOUs") and
Contract Research Organizations ("CROs"). These methods are important
because they open up international channels of communication, both in private
industry and between regulatory agencies, which may ultimately result in the
increased acceptability of foreign clinical data.
1. Memorandums of Understanding. A Memorandum of Understanding is an
agreement involving an exchange of information between two drug regulatory
agencies. MOUs provide for an exchange of inspection report results, an
evaluation of the reports by the authority requesting the inspection, and the
reciprocal or joint use of inspectors. 94
MOUs, once executed between the U.S. and a foreign country, establish the
legal basis for FDA reliance upon inspections of pre-clinical laboratories and
pharmaceutical manufacturing plants conducted by foreign inspectors. 95 FDA
is willing to accept studies received from those foreign laboratories based on the
inspections performed, and assurances given, by the foreign drug regulatory
agency.
However, there are two problems associated with MOUs. The first is that
there are no MOUs in the clinical inspection area; none have even been
discussed.% The second problem with MOUs relates to their enforcement.
Since an MOU is technically an agreement rather than a contract, the parties
must act in good faith to honor their promises when conducting inspections and
recording their results. Assuming that this good faith requirement will be upheld,
MOUs are one of the most important ways to increase the acceptability of
foreign clinical data because agencies share information about regulatory
requirements and particular pharmaceutical manufacturers. Hopefully, if such
MOUs continue their success at the pre-clinical level, this can foster a
relationship between the regulatory agencies to open the door to future
discussions on an MOU program for clinical studies.
94. Buday, Worldwide Drug Regulatory Controls-Are They/Will They Become Uniform?, DRUG
INFO. J. 47, 52 (Apr.-June 1980). See also Halperin, supra note 19, at 160. FDA has executed MOUs
with Switzerland, Sweden and Canada for mutual acceptance of Good Manufacturing Practice
inspections. Similarly, FDA has MOUs covering Good Laboratory Practice inspections with
Switzerland, Sweden, Canada, and Japan. FDA annually meets with representatives of the Canadian
Health Protection Branch and the U.K. Department of Health and Social Security to discuss problems
covering all aspects of agency programs including foods, drugs, cosmetics and medical devices. In
addition to Canada and the U.K., FDA holds individual bilateral meetings with a number of countries
including Italy, Sweden, Hungary, Israel, Egypt, Finland, Brazil, and Japan.
95. The FDA also maintains its own foreign inspection activities, sending inspectors to drug
manufacturing plants all over the world to determine whether or not products they produce are
suitable for import into the U.S. See Lisook, supra note 23.
96. Telephone interview, supra note 45.
1991]
15
Gorski: An FDA-EEC Perspective on the International Acceptance of Foreign
Published by CWSL Scholarly Commons, 1991
344 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 21
2. Contract Research Organizations. A CRO is a corporation which acts as an
independent contractor to perform clinical studies on behalf of the sponsor.
97
CROs are useful because they allow a sponsor to accomplish demanding clinical
research programs without the need for an internal short term increase in
staff.9 CROs design drug study protocols, locate and hire clinical investigators
to perform the studies, prepare and send the required patient evaluation and
reporting forms to the clinical investigators, monitor the studies for the sponsor,
tabulate the data that is compiled, and prepare the final reports for the
sponsor.99
Before a CRO is actually employed, the sponsor must qualify the CRO to
determine if it is capable of performing the study.1t° For example, prior to the
instigation of the study, the CRO must be able to identify, qualify and approve
investigators, inspect and qualify clinical laboratories, assist with independent
review boards or ethics committee review, audit the progress of the study, and
allow periodic monitoring of reports.'0 ' The single most important factor to
ensure satisfactory CRO performance is to examine the CRO's management
supervision of the people who actually do the day-to-day work, because workers
will rarely deliver a better quality product than management demands.10
If the foreign clinical studies are adequately prepared by the sponsor and the
CRO, the FDA may be more willing to accept future studies. Once the FDA
becomes familiar with particular CROs, they may be more willing to accept a
study from a foreign corporation using a reputable CRO.
By reviewing the foregoing sections, it is apparent that the FDA has expended
considerable effort in establishing standards for accepting foreign clinical data.
Similarly, the EEC has attempted to facilitate the use and acceptability of foreign
clinical data.
97. "Contract research organization' means a person that assumes, as an independent
contractor with the sponsor, one or more of the obligations of a sponsor, e.g., design of a protocol,
selection or monitoring of investigations, evaluation of reports, and preparation of materials to be
submitted to the Food and Drug Administration." 21 C.F.R. § 312.3 (1990).
98. Sewell,Identification and Qualification of Foreign Contract Research Organizations, 22 DRUG
INFO. J. 173 (1988).
99. Leo Winter Assoc., Inc. v. Dep't of Health & Human Services, 497 F. Supp. 429, 431 (D.C.
Cir. 1980). The District Court held that a contract research organization is subject to the regulatory
controls imposed by FDA "[b]ecause [the CRO] has assumed the technical responsibility placed upon
manufacturers and sponsors, [and because] it has also assumed the obligations imposed on sponsors
by the Act, and subjected itself to investigations authorized by the [Act]. Any conclusion to the
contrary would subvert the remedial purposes of the legislation and significantly undermine its
effectiveness." Id
100. Sewell, supra note 98, at 174-75. The various pitfalls which the sponsor must address are
the location of a CRO; method of contacting the CRO; IND status; delegation of responsibilities for
the CRO; time frames; contract requirements; IRB/Ethics committee review; informed consent;
source document review; standard operating procedures; drug accountability; adverse events reporting;
and monitoring reports.
101. Id
102. Id
16
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III. EEC POLICY
A. EEC Legislation
The EEC was established in 1957 under the Treaty of Rome which clearly
defined its aim as the free movement of goods and services between its Member
States."0 3 The Treaty was designed to promote a harmonious development of
economic activities between the Member States belonging to the Community. 4
The Treaty was also designed to promote a continuous and balanced expansion,
an increase in stability, a higher standard of living, and closer relations between
the Member States.105
One of the categories of goods and services affected by this free movement
ideology is the pharmaceutical industry. The EEC Commission'06 has adopted
numerous regulations regarding the sale and approval of new drugs and
pharmaceutical chemicals among the Member States to increase available health
care to its citizens and to reduce trade barriers within the Community.107 An
examination of these standards is necessary in order to understand the barriers
which inhibit, and the solutions to encourage, the acceptance of foreign clinical
data.
B. Regulation of Proprietary Medicinal Products
The EEC Commission has passed numerous Directives' °8 which regulate the
sale and approval of proprietary medicinal products1°9 within the Community.
103. P. KATEYN & P.V. VAN THEMAAT, INTRODUCTION TO THE LAW OF THE EUROPEAN
COMMUNMES 15 (1973).
104. G. MYLES, 1 EEC BRIEF, Legal Order, 11 (Supp. 1986).
105. Id
106. Subject to Article 157 of the EEC Treaty, the Commission consists of at least one, but no
more that two, members having the nationality of the Member States. It has been agreed that the
larger Member States (Germany, Spain, France, Italy and the United Kingdom) should have two
Commissioners and the seven smaller Member States should have one Commissioner. See G. MYLES,
supra note 104, Commission, 05.
107. For a list of the Community regulations relating to proprietary medicinal products, see The
Rules Governing Medicinal Products for Human Use, infra note 109, at table of contents.
108. A Directive is secondary Community law which "shall be binding, as to the result achieved,
upon each Member State to which it is addressed but shall leave to the national authorities the choice
of form and method." EEC Treaty, art. 189, reprinted in G. MYLES, supra note 104, Legal Order, l
17.
109. A proprietary medicinal product is "any ready-prepared medicinal product placed on the
market under a special name and in a special pack." Medicinal product is defined as
any substance or combination of substances presented for treating or preventing disease
in human beings or animals. Any substance or combination of substances which may
be administered to human beings or animals with a view to making a medical diagnosis
or to restoring, correcting or modifying physiological functions in human beings or in
animals is likewise considered a medicinal product.
17
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The primary purpose of these rules is to safeguard the public health."
However, in establishing such rules, consideration must be given to the
pharmaceutical industry so that research and trade in medicinal products is not
hindered."n
1. EEC Standard for Accepting Foreign Clinical Data. In order to achieve a
balance between the public health and the promotion of medicinal products
within the Community, the original 1965 standard ("65/65/EEC") for accepting
clinical data offered to support a marketing authorization was broad: "The sole
criteria which may be taken into consideration by the Member States during the
examination of an application for authorization are the quality, safety and
efficacy of the product concerned.""2 Additionally, 65/65/EEC states that the
marketing authorization "shall be refused if. . . it113 proves that the proprietary
medicinal product is harmful in the normal conditions of use, or that its
therapeutic efficacy is lacking or is insufficiently substantiated by the applicant,
or that its qualitative or quantitative composition is not as declared.""4
This broad language has created problems, however. Since the 65/65/EEC
standard is so broad, Member States interpret the criteria differently, which leads
to various results concerning the same clinical data." 5
2. Problems with Interpreting the EEC Standard. Due to the broad scope of
65/65/EEC for accepting clinical data, interpretational problems have arisen,
particularly when the standard is applied to foreign clinical data. Interpretation-
al conflicts occur because, although all the Member States use the same standard
O. EUR. COMM. (No. L 22) 369 (1965) [hereinafter 65/65/EEC], reprinted in COMMISSION OF THE
EUROPEAN COMMUNITIES, I THE RULES GOVERNING MEDICINAL PRODUCTS IN THE EUROPEAN
COMMUNITY 23 (1989) (The Rules Governing Medicinal Products for Human Use in the European
Community) [hereinafter The Rules Governing Medicinal Products for Human Use].
This five volume set of materials is the most helpful information to put all of the EEC regulations
into perspective regarding the approval and distribution of medicinal products. Volume I, cited
above, is entitled The Rules Governing Medicinal Products for Human Use in the European
Community; Volume I1 is entitled Notice to Applicants for Marketing Authorizations for Medicinal
Products for Human Use in the Member States of the European Community; Volume III is entitled
The Guidelines on the Quality, Safety and Efficacy of Medicinal Products for Human Use; Volume
IV is the Guide to Good Manufacturing Practices for the Manufacture of Medicinal Products; and
Volume V is The Rules Governing Medicinal Products for Veterinary Use in the European
Community.
110. Id.
111. Id.
112. 65/65/EEC at 369, reprinted in The Rules Governing Medicinal Products for Human Use,
supra note 109, at 8.
113. "It" refers to the regulatory authority which rendered a decision on an application for
marketing authorization. In accordance with Article 12 of Directive 65/65/EEC, all decisions rendered
by the Member States in granting a marketing authorization must be published. The name and
address of the Official Journal in each Member State can be found in the Notice to Applicants, infra
note 123, at 6.
114. 65/65/EEC, reprinted in The Rules Governing Medicinal Products for Human Use, supra
note 109, at 27.
115. The Rules Governing Medicinal Products for Human Use, supra note 109, at 9.
18
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in accepting foreign clinical data, different opinions are reached on the same pre-
clinical or clinical data.116 Opinions differ because regulatory authorities are
often influenced by the historical background or past practice of the Member
State from where the data was received, rather than the quality of the data
itself.117  Moreover, "due to national differences in medical schools, the
harmonization of procedures does not ensure that the results of the standardized
procedures are similarly evaluated." 18
In order to reduce the different opinions being reached by the Member States
on the same clinical data, in 1977 the EEC Commission handed down
75/319/EEC which created a Committee for Proprietary Medicinal Products"9
("CPMP") to assist the Member States in developing a consistent interpretation
of the EEC standard. The CPMP's goal is to achieve a balance between the
considerations of public health and the promotion of medicinal products within
the Community.' The purpose of the CPMP is to facilitate the adoption of
a common position by the Member States regarding the approval of marketing
authorizations for new medicinal products.'21 Adopting a common position
would promote the free movement of proprietary medicinal products within the
Community and would provide patients with improved access to new drugs."
C. Resolution of Differing Opinions
The CPMP, in order to reduce the different opinions rendered by the Member
States on the same clinical data, recently created three methods which help
interpret the 65/65/EEC standards. These methods consist of a new set of
application guidelines known as the "Notice to Applicants," the use of updated
information packets known as "assessment reports," and a Note for Guidance
prepared by the CPMP Working Party on Efficacy of Medicinal Products entitled
Good Clinical Practice for Trials on Medicinal Products in the European
Community.
116. See Jones, UK Applications Submitted to the CPMP, 20 DRUG INFO. J. 373, 376 (1986).
For example, since the multi-state procedure for obtaining marketing authorization in the EEC was
established, at least 38 applications for marketing authorization have been objected to by at least one
Member State so that all 38 applications have been referred to the CPMP. See Teijgeler, infra note
117.
117. Teijgeler, The Committee for Proprietary Medicinal Products (CPMP)-Past History and
Future Changes, 20 DRUG INFO. J. 367, 368 (1986).
118. Kaufer, The Impact of Regulation on New Product Development in the Drug Industry: A
European Perspective, in DEREGULATION OR RE-REGULATION? REGULATORY REFORM IN EUROPE AND
THE UNITED STATES 171 (G. Majone ed. 1990).
119. OJ. EuR. COMM. (No. L 147) 13 (1975) [hereinafter 75/319/EEC].
120. Teijgeler, supra note 117, at 369.
121. 75/319/EEC, supra note 119, at 15.
122. See Teijgeler, supra note 117, at 369.
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1. Notice to Applicants. The Notice to Applicants2 3 was recently published
to facilitate the application procedure used in the EEC for medicinal products.
Its purpose is to aid regulatory authorities in establishing a consistent set of
application guidelines and procedures.1 24 The CPMP hopes that the use of a
standardized set of guidelines will reduce different opinions given to the clinical
data by the regulatory authorities.12 The CPMP reasons that if the application
procedure is consistent throughout the EEC, a regulatory agency can more easily
grant a marketing authorization for a new medicinal product if another Member
State has already done so from the same application.'26
The Notice contains the requirements to sufficiently organize and present the
data to a regulatory authority when applying for a marketing authorization.12 7
The Notice also describes, in detail, the administrative steps to follow when
applying for a marketing authorization according to the multi-state proce-
dure.12 The multi-state procedure enables a company which has previously
obtained marketing authorization from one Member State to request the
extension of that authorization to two or more other Member States. 129 The
123. COMMISSION OF THE EUROPEAN COMMUNITIES, 2 THE RULES GOVERNING MEDICINAL
PRODUCTS IN THE EUROPEAN COMMUNITY (1989) (Notice to Applicants for Marketing Authorizations
for Medicinal Products for Human Use in the Member States of the European Community)
[hcreinafter Notice to Applicants].
124. Id. at 3.
125. Id.
126. Id See generally Schnieders, Evaluation Report of the CPMP, 20 DRUG INFO. J. 377 (1986).
127. Notice to Applicants, supra note 123, at 3. The Notice to Applicants provides all the
information necessary to submit an application to any one of the Member States. A brief overview
of the topics covered in the manual include: preparing an application based upon the multi-state
procedure (subject to Directive 83/570/EEC); preparing an application based upon the special
concertation procedure for biotechnology or high technology medicinal products (subject to Directive
87/22/EEC); general information regarding basic guidelines and authorities to contact regarding the
application; and two separate annexes which describe the standard format for applications in the EEC
and the use of expert reports in support of an application.
In Annex I, requirements are listed as to the form and structure of the submission of the general
administrative data: the chemical and pharmaceutical documentation, the pharmacological and
toxicological documentation, and the clinical documentation. In Annex II, requirements are listed as
to the presentation of the expert reports which must be submitted by the manufacturer as part of the
application. For example, the expert must comment on the suitability of the animals used, the
experimental conditions, and the reliability and applicability of the results.
128. Id. at 5. There are two application procedures, in addition to purely national registration
procedures, which are intended to facilitate the adoption of a common position by Member States
on applications for authorization of medicinal products. The first (and more widely used) procedure,
governed by 83/580/EEC, is known as the multi-state procedure and enables a company which has
previously obtained authorization from one Member State to request the extension of that
authorization to two or more other Member States. The Member States who receive an application
are obliged to take the original authorization into due consideration and should normally grant
authorization within 120 days. However, if a Member State is not satisfied with the application, it
may lodge its reasoned objection with the CPMP which is then required to give an opinion as to
whether the product satisfies the criteria for authorization. For further details, see The Rules
Governing Medicinal Products for Human Use, supra note 109, at 10-11.
The second and more recently established procedure, governed by 87/22/EEC, applies to
medicinal products derived from biotechnology. The CPMP issues an opinion on whether the product
satisfies the criteria for authorization laid down in the Community Directives. This opinion is
communicated to the Member States who are required to reach a definitive decision within 30 days.
129. Notice to Applicants, supra note 123, at 5.
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multi-state procedure assists pharmaceutical manufacturers in distributing their
product throughout the EEC by requesting that additional Member States grant
marketing authorization after one Member State has already done so.
Finally, the Notice provides general guidance on how the applications should
be presented, the order of presentation, and the content of the dossier."8 The
Notice is important because it requires applicants for marketing authorizations
to use the same application procedure, thereby making it more difficult for drug
regulatory agencies to justify different opinions rendered on the same clinical
data presented in the same format.
2 Assessment Reports. Besides the Notice to Applicants, the CPMP, in its
effort to reduce the different opinions rendered on the same clinical data, also
created assessment reports. Member States use assessment reports when
considering applications based on the multi-state procedure.
Once an application for a marketing authorization has been submitted to one
of the regulatory authorities of a Member State, the regulatory authority must
draft an assessment report and comment on the application.31 The assessment
report acts as an update, summarizing the application as it was decided by the
agency which received the original application. 32 It must be prepared the first
time each agency receives an application for a new substance, irrespective of
whether the decision to distribute the new substance is positive or negative. 133
Furthermore, it is drawn up at each phase of the approval and kept up to date
after approval.'1  The up-dated information includes a summary of any
additional data, agency assessments and conclusions of this data, the action taken
by the agency, and the up to date summary of the product characteristics. 135
The agency is then required to forward the assessment report to other regulatory
agencies where marketing authorization is sought.'3
The assessment report is beneficial because it allows Member States to
exchange and evaluate respective decisions regarding the approval or rejection
of specific applications. In the future, the exchange of the reports should help
provide for a consistent evaluation of an application. 37 The reports should
also help in evaluating the practice of both the manufacturers and the regulatory
agencies, which is necessary for reaching the goal of mutual recognition of
clinical data. 38
3. Good Clinical Practice for Trials on Medicinal Products in the European
130. Poggiolini, Drug Registration in Europe and the EEC, 20 DRUG INFO. J. 363, 364 (1986).
131. Id at 363-64.
132. Schnieders, supra note 126, at 380.
133. Id.
134. Id
135. Id.
136. Id.
137. Id at 382.
138. The Rules Governing Medicinal Products for Human Use, supra note 109, at 2.
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Community. In November 1990, the CPMP Working Party on Efficacy of
Medicinal Products published a Note for Guidance entitled Good Clinical
Practice for Trials on Medicinal Products in the European Community.39 As its
name implies, the objective of this guideline is to establish the principles for the
standard of good clinical practices for trials on medicinal products in human
beings within the EEC. The stated purpose of the guideline is for
[a]ll parties involved in the evaluation of medicinal products [to]
share the responsibility of accepting and working [subject] to such
standards in mutual trust and confidence. Pre-established, systematic
written procedures for the organization, conduct, data collection,
documentation and verification of clinical trials are necessary to
ensure that the rights and integrity of the trial subjects are thorough-
ly protected and to establish the credibility of data and to improve
the ethical, scientific and technical quality of trials. These procedures
also include good statistical design as an essential prerequisite for
credibility of data and moreover, it is unethical to enlist the co-
operation of human subjects in trials which are not adequately
designed. [This includes] all data, information and documents
[which] may be confirmed as being properly generated, recorded and
reported." °
The significance of this guideline can not be over emphasized, as the standards
set forth dictate how the clinical trials should be operated in order to assure
acceptance of clinical data in support of a marketing authorization. Also, the
guideline thoroughly discusses various aspects of clinical testing which are either
not addressed at all, or insufficiently addressed, by its FDA counterpart. 4' For
example, the glossary defines such terms as a case report form, 42 good clinical
practice, 4 3 quality assurance,144 and trial master file," 5 none of which are
139. COMMISSION OF THE EUROPEAN COMMUNITIES, CPMP Working Party on Efficacy of
Medicinal Products, Good Clinical Practice for Trials on Medicinal Products in the European
Community (1990) (approved by the CPMP, Nov. 1990; effective July 1, 1991) (available from the
Commission of the European Communities, Rue de ]a Loi 200, 8-1049, Brussels, Belgium).
140. lId at 1 (Foreword).
141. For the sake of brevity, differences between FDA policy and EEC policy, based upon this
new guideline, are discussed in subsequent footnotes rather than in the text. See infra notes 142-60
and accompanying text.
142. A case report form is defined as "a record of the data and other informat;on on each
subject in a trial as defined by the protocol. The data may be recorded on any medium, including
magnetic and optical carriers, provided that there is assurance of accurate input and presentation, and
allows verification." Good Clinical Practice for Trials on Medicinal Products in the European
Community, supra note 139, at 6.
143. Good clinical practice is defined as "a standard by which clinical trials are designed,
implemented and reported so that there is public assurance that the data are credible, and that the
rights, integrity and confidentiality of subjects are protected." Id at 8.
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defined by FDA. Additionally, some definitions in the glossary are more
demanding or more comprehensive than their FDA counterpart, such as: audit
(of a trial),'4 clinical trial,'47 investigator, 14 and protocol.'49
Besides the glossary, the guideline contains five chapters which explain the
most important aspects of performing a clinical trial and which identify those
areas that require closer scrutinization by the sponsor before an application for
marketing authorization is sought. The first section covers the protection of trial
subjects,5 ' consultation by ethics committees,' and properly obtaining
144. Quality assurance is defined as "systems and processes established to ensure that the trial
is performed and the data are generated in compliance with Good Clinical Practice including
procedures for ethical conduct, SOPs, reporting, personal qualifications etc. This is validated through
in-process quality control and in- and post-process auditing, both being applied to the clinical trial
process as well as to the data." Id at 10.
145. A trial master file is "a hard copy of all the documentation relating to a clinical trial ..
Id at 12.
146. The glossary indicates that an audit "must be conducted either through an internal facility
at the sponsor but independent of the units responsible for clinical research, or through an external
contractor." Id at 5 (emphasis added). The FDA, on the other hand, does not require audits.
147. The glossary defines clinical trial as "any systematic study on medicinal products in human
subjects whether in patients or non-patient volunteers in order to discover or verify the effects of
and/or identify any adverse reaction to investigational products, and/or to study their absorption
distribution, metabolism and excretion in order to ascertain the efficacy and safety of the products."
Id at 6. The FDA, however, omits dosage studies from its definition of clinical trial.
148. The glossary defines an investigator as:
one or more persons responsible for the practical performance of a trial and for the
integrity, health and welfare of the subjects during trial. The investigator is:
" an appropriately qualified person legally allowed to practice medicine/dentistry,
" trained and experienced in research, particularly in the clinical area of the proposed
trial,
" familiar with the background to and the requirements of the study,
" known to have high ethical standards and professional integrity....
Id at 9. The FDA does not require the investigator to possess an M.D. or a D.D.S.
149. Protocol is defined as "a document which states the rationale, objectives and statistical
design and methodology of the trial, with the conditions under which it is to be performed and
managed. A list of items to be included in the protocol is given in the Annex." Id at 10. The Annex
then spells out, at length, the items which should be covered in the protocol, such as: general
information, justification and objectives, ethics, a general time schedule, general design, subject
selection, treatment, assessment of efficacy, adverse events, practicalities, handling of records,
evaluation, statistics, financing, reporting, approvals, insurance, a summary, any relevant supplements,
and any references. Id at 39-43. This explanation and the relevant portions of the annex make this
definition of protocol much more comprehensive than that of the FDA.
150. The guideline indicates that the Declaration of Helsinki is the accepted basis for clinical
trial ethics.
151. The guideline indicates that the "sponsor and/or investigator must request the opinion of
relevant Ethics Committee(s) regarding suitability of clinical trial protocols ... and of the methods
and material to be used in obtaining and documenting [patient] informed consent." Good Clinical
Practice for Trials on Medicinal Products in the European Community, supra note 139, at 13 (emphasis
added). However, the guideline goes on to say that the "[s]ponsor/investigator should consider
recommendations made by the Ethics Committee," thereby indicating that the sponsor/investigator
is not compelled to follow the ethics committee recommendation(s).
Regardless of whether their recommendations are mandatory, the Ethics Committee should
consider the following aspects of the proposed clinical trial which are beyond FDA requirements:
[Tihe suitability of the protocol in relation to the objectives of the study, its scientific
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patient informed consent.112 The second section discusses the responsibilities
of the sponsor,5 3 monitor,54 and investigator 5' during the performance of
the clinical trial. 5 6 The third section explains how to handle the data derived
from the clinical trial, Le., the duties of the investigator and sponsor, archiving
the data, and which language to use. 57 The fourth section discusses how to
use statistics throughout the performance of the clinical trial, particularly in
experimental design, randomization and blinding, and statistical analysis. 58
Lastly, a system of quality assurance must be employed and implemented by the
sponsor, conducted by persons or facilities independent of those responsible for
the trial. 15 9
Finally, at the end of the guideline is an annex which is intended to provide
efficiency i.e. the potential for reaching sound conclusions with the smallest possible
exposure of subjects, the justification of predictable risks and inconveniences-weighed
against the anticipated benefits for the subjects and others....
[Pirovision for compensation/treatment in the case of injury of death of a subject if
attributable to a clinical trial, and any insurance or indemnity to cover the liability of
the investigator and sponsor....
152. The guideline indicates that the Declaration of Helsinki should be implemented in each
clinical trial concerning the principles of informed consent. However, the guideline appears to permit
oral consent where an independent witness can record the patient's consent. Id. at 16. The FDA,
however, does not permit such oral consent. Additionally, the guideline indicates that "[c]onsent must
always be given by the signature of the subject in a non-therapeutic study, i.e., when there is no direct
clinical benefit to the subject." Id The FDA has no such distinction.
153. The guideline indicates numerous duties which go beyond FDA requirements for which
the sponsor is accountable. For example, the sponsor must establish detailed standard operating
procedures to comply with good clinical practices; must conduct an internal audit of the trial; must
submit notification/application to the relevant regulatory authorities; must ensure submission of any
necessary documents to the Ethics Committee; must ensure communication of any modification,
amendment or violation of the protocol (if the change may impact on the subject's safety); must
inform the investigator and relevant authorities about discontinuation of the trial and the reasons
therefore; must retain sufficient samples of each batch and a record of its analyses and characteristics
for reference so that there is the possibility for an independent laboratory to re-check the
investigational products; and the sponsor must provide adequate compensation or treatment for
subjects in the event of trial related injury or death, and provide indemnity (legal and financial) for
the investigator, except for claims resulting from malpractice and/or negligence (cf FDA regulations
which only require a statement in the patient consent form on whether compensation is available).
IP at 17-19.
154. The guideline indicates that a "monitor" is the principal communication link between the
sponsor and the investigator and, as such, has numerous responsibilities. Id at 20. The FDA has no
similar requirement.
155. The investigator is responsible for a number of duties which go beyond FDA regulations.
For example, the guideline indicates that the investigator is responsible for making all data available
to the sponsor/monitor and any other relevant authority for verification, audit, or inspection purposes,
whereas there is no sponsor access to medical records in FDA regulations (the FDA recommends that
it be in the patient consent form). Also, the guideline indicates other areas for which the investigator
is responsible, e.g., providing fully functional resuscitation equipment in case of emergency, etc.,
whereas the FDA regulations do not specifically include these additional requirements.
156. Good Clinical Practice for Trials on Medicinal Products in the European Community, supra
note 139, at 17-24.
157. Id at 25-28.
158. Id at 29-30.
159. Id at 31.
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guidance on some of the practical aspects of clinical trials. t6° For example, it
briefly defines the four phases of clinical trials related to the development of
medicinal products; it indicates measures to ensure optimal trial conditions; it
describes what the trial protocol must consist of; it describes the purpose of the
case report form; it indicates what information must be disclosed regarding the
financing of the trial; and it also discusses insurance and liability aspects,
labelling, and systems of notification or approval of clinical trials.
The careful analysis and preparation contained in the guideline indicates that
the CPMP is committed to obtaining a consistent recognition of clinical data in
the EEC. Hopefully, the guideline, along with the Notice to Applicants and the
assessment reports, will assist pharmaceutical manufacturers in obtaining
marketing authorization earlier than before.
4. Future Trends. The recent developments of the Notice to Applicants,
assessment reports, and the guideline on good clinical practice are encouraging
because they increase communication between drug regulatory agencies which
can foster the increased acceptability of foreign clinical data. For example, the
Notice to Applicants procedure is increasingly being used by other Western
European countries which are not members of the European Community. 6
In addition to increasing communication between regulatory agencies, these
three methods can also reduce the different opinions reached on the same
clinical data by the Member States. This can be explained by briefly examining
the CPMP appeals process.
The CPMP employs an appeals process to reduce the different opinions on the
same clinical data.162 When a pharmaceutical manufacturer has received a
marketing authorization from one Member State, the multi-state procedure is
usually employed so that marketing authorizations can be acquired from two or
more other Member States. 63  On the basis of the application and the
authorization granted by the first Member State, the authorities of the Member
States to which the application is addressed have 120 days to grant authorization
to market the product in their country, or to formulate reasoned objections.16
Where one or more objections are advanced, the matter is referred to the CPMP
which considers the grounds for the objections, and any written or oral
explanations provided by the applicant, before issuing its own reasoned opinion
within sixty days. 65
This appeals process should help the CPMP in reducing the different opinions
on the same clinical data because the individual regulatory agencies must now
160. Id at 35-46.
161. Notice to Applicants, supra note 123, at 2.
162. It should be noted that the CPMP can only make suggestions as to the acceptance or
rejection of a certain application; the decision is not binding on the Member State. See Notice to
Applicants, supra note 123, at 3.
163. See supra notes 128-129 and accompanying text.
164. Notice to Applicants, supra note 123, at 5.
165. Id.
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follow the Notice to Applicants, assessment reports, and good clinical practice
procedures. These procedures help the CPMP reduce the different opinions
because they decrease the possibility of a regulatory agency basing their rejection
of a particular application on an invalid reason, such as the source of the clinical
data. The CPMP, by acting as a watchdog over the individual regulatory
agencies, can ensure that these procedures are being properly followed and that
the agencies are basing their decision to approve or reject an application on the
proper factors. Consequently, the threat of appeal to the CPMP should deter
regulatory agencies from basing a rejection of a marketing authorization on such
a factor as the source of the foreign clinical data.
The Notice to Applicants, assessment reports, and the guideline to good
clinical practice should be required on an international scale so that an exchange
of information can occur between more countries, and not just between those
located in Europe. For example, the FDA could benefit from the use of
assessment reports in determining the basis for another agency's decision to
approve or reject a particular new drug. In the long run, what may come out of
such guidelines is a common application format, along with common guidelines
for good clinical practice, not only for the EEC countries, but also the U.S. and
perhaps the rest of the international community. 166
IV. REDUCING THE BARRIERS WHICH INHIBIT THE INTERNATIONAL
ACCEPTANCE OF FOREIGN CLINICAL DATA
A. Understanding the Barriers
The decisive factor in assessing an application for marketing authorization
should be the quality of the clinical data, irrespective of origin. 167 The reasons
for concentrating on the quality of the clinical data, as opposed to concentrating
on its origin, are both legal and scientific. 68 First, as explained above, both
FDA and EEC laws require it. 169 Second, from the scientific standpoint, data
generated in one country is nearly always applicable in other countries; the
exceptions lie only where ethnic factors may prohibit extrapolation or where
medical terminology varies.170
Unfortunately, however, quality is not always the only factor considered by a
drug regulatory agency when reviewing an application. Two different but related
factors that inhibit the acceptability of foreign clinical data are: 1) national
barriers, and 2) economic and political forces.
1. National Barriers. "[Niational barriers should not inhibit the international
166. See Teijgeler, supra note 117, at 370.
167. Knabe, Acceptance of Foreign Clinical Data in Industy, 22 DRUG INFO. J. 137, 139 (1988).
168. Jones, supra note 70, at 95.
169. See supra notes 27-44, 108-15 and accompanying text.
170. Jones, supra note 70, at 95.
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movement of a new and more effective drug product. The consumer is entitled
to as much product effectiveness as the industry can safely deliver in the
particular drug, once safety is reasonably shown."171
National barriers act as a type of prejudice against another country's standards
for granting a marketing authorization. For example, if a regulatory agency in
the EEC grants a marketing authorization for a new medicinal product, then
distribution of that product can only occur within the boundaries of that
Member State. If the sponsor of the marketing authorization seeks to distribute
the product to other Member States, the multi-state procedure is used and the
second Member State receives the application and reviews the original marketing
authorization granted by the first Member State." 2 The second Member State
can then reject the marketing authorization based upon its opinion that the
quality of the data is deficient, and it can discredit the original Member State's
approval if it believes the procedures employed by the original Member State
were inadequate.
Although the procedures employed by the original Member State are certainly
a legitimate concern for the subsequent Member State reviewing the application,
often this is only used as an excuse to reject a particular application. Thus, even
though national barriers are not to be taken into account, regulatory agencies
are often influenced by the historical background of the Member State in
question rather than on the quality of the data supplied. Since the goal of
every pharmaceutical company or drug regulatory agency must be to increase the
safety and usefulness of drugs reaching the marketplace, "we should question
whether a national border is an appropriate dividing line" 74 for the acceptabili-
ty of foreign clinical data.
2. Economic and Political Forces. "[D]ifferent cultures can make very different
value judgments about important life-sustaining drugs.... [Elach nation makes
its own judgment of what levels of harm can be tolerated by its people.""5
Economic and political forces can be explained in terms of a risk balancing
which involves a number of nonmedical or nonsafety judgments for the people
guarding the gate of drug product entry into a nation.1% Agency officials often
engage in trade-offs between economic and political forces which can compete
with the decision to grant or deny a particular application. For example, in a
particular country there may be a higher cost for the drug, there may be a
disadvantage to an indigenous industry, or there may be a higher potential for
adverse reactions which may alter an agency's decision to grant approval for a
171. O'Reilly, supra note 11, at 133.
172. See supra notes 128-129 and accompanying text.
173. Teijgeler, supra note 117, at 368.
174. O'Reilly, supra note 11, at 132.
175. Id at 136.
176. Id at 133.
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particular new drug. t" Additionally, in the EEC, a "'marketing authorization'
by a national drug regulatory agency is no permission to actually market the
product. In most Member States a new drug has to pass through a lengthy
evaluation process to determine its economic benefits and costs for the purpose
of fixing its price and reimbursement rate."178
Political accountability is also involved. If an agency official is expected to be
accountable for a particular regulatory decision regarding a new drug application,
a decision to grant approval may change. For example, "[t]he 'Weiss effect t79
or the 'Waxman scenario ' 80 are critiques of FDA staff performance which
directly impact on future discretionary decisions of FDA employees. The French
or German civil services presumably face their own equivalents of political
accountability for drug decisions." 8'
Because of external forces such as national barriers and economic and political
forces, drug regulatory agencies do not rely solely on the quality of the data
supplied by the sponsor in the new drug application. Accordingly, these barriers
must be reduced in order to increase the acceptability of foreign clinical data,
which will result in improved health care by increasing the availability of new
drugs.
B. Reducing the Barriers
Regulatory agencies should take a threefold approach to reduce the barriers
which block the acceptance of foreign clinical data: increase methods of
communication between agencies through the use of MOUs, CROs, and
assessment reports; reduce economic and political pressures; and establish an
international drug dossier.
1. Increasing Methods of Communication. As discussed above, the FDA has
employed Memorandums of Understanding with various national health
authorities. 182 This method of opening up channels of communication may be
the best method to increase the acceptance of foreign clinical data because the
regulatory agencies themselves instigate these agreements. By voluntarily
opening channels of communication between themselves, regulatory agencies
observe what procedures are being used in other countries. Since MOUs also
177. Id.
178. Kaufer, supra note 118, at 172 See also O'Reilly, supra note 11, at 137.
179. The "effect" comes from the relentless questioning of FDA decisions during hearings
conducted by Rep. Ted Weiss, Hearings, The Regulations by the Department of Health and Human
Services of Carcinogenic Color Additives, Before a Subcomm. of the House Comm on Government
Operations, 98th Cong., 2d Sess. 511 (1984). O'Reilly, supra note 11, at 136 n.19.
180. Chairman Waxman's efforts to change new drug approval processes led ultimately to the
1984 legislation, Pub. L. No. 97-417, 98 Stat. 1585 (1984), and he pressed FDA to make changes.
Hearings, Drug Legislation, Before a Subcomm. of the House Comm on Energy and Commerce, 98th
Cong., 1st Sess. (1983). O'Reilly, supra note 11, at 136 n.20.
181. O'Reilly, supra note 11, at 136.
182. See supra notes 94-96 and accompanying text.
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involve the joint use of inspectors and the exchange of inspection report
results,l regulatory agencies are constantly involved in communication with
other agencies. As a result, the agencies will eventually grow familiar with one
another, which can result in the acceptance of clinical data, and not just pre-
clinical data.18 Once such familiarity is established between regulatory
agencies, personnel from the respective agencies and also private industry can
anticipate what procedures must be employed to achieve an acceptable standard
for the foreign clinical data.
CROs can also facilitate the acceptance of foreign clinical data because, once
properly qualified by a regulatory agency, the agency may be more willing to
accept a future study from that particular CRO. The more often a particular
CRO is used, the more often a regulatory agency is likely to accept the foreign
clinical data because the agency has become familiar with the CRO through
experience.
Unfortunately, using MOUs and CROs to achieve the goal of mutual
recognition appears utopian in nature because this requires regulatory agencies
to expend a great deal of time, effort and money. One solution to this involves
requiring assessment reports on an international scale. Assessment reports
should be required on an international scale because this would provide every
drug regulatory agency in the world with an updated history of the new drug
product. This way, drug regulatory agencies will stay apprised of new drugs
being approved by other agencies, with the hope that deference will be granted
to an agency which has already granted marketing authorization to a sponsor for
a new drug product. Also, since the CPMP has already undertaken such a
procedure, the application of assessment reports internationally would not be
extremely costly or time consuming; regulatory agencies would merely have to
require the use of such reports internationally and make available to sponsors
the appropriate information and forms. If mutual recognition of foreign clinical
data is to occur, assessment reports must be required on an international scale
to increase the methods of communication between nations.
2. Reducing Economic and Political Forces. As discussed above, acceptability
of a foreign study by FDA, CPMP, and other authorities has often been
conditioned upon external forces rather than on the quality of the data itself.L1
Consequently, the harmonization of national laws alone will not result in the
same attitude on the part of drug regulatory agencies to accept or deny a
particular application, nor will the same results be achieved.18 Thus, economic
and political factors must also be reduced so that a consistent evaluation of
applications can occur.
In order to minimize economic effects upon a sponsor seeking approval for a
183. See Buday, supra note 94 and accompanying text.
184. See generally Buday, supra note 94, at 49; Halperin, supra note 19, at 153.
185. See supra notes 167-81 and accompanying text.
186. Teijgeler, supra note 117, at 368.
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new drug, the best advice is to obtain information about the foreign regulatory
agency before the approval process begins. For example, consultants can be
retained to recommend what local customs exist in processing the product
approval or other clearance. t87 The firm requesting foreign approval should
also allocate additional time in seeking approval, especially for the unforeseen
procedural pitfalls, such as translation. l88
Although it is unrealistic to think that economic pressures will fully dissolve,
the pharmaceutical manufacturer can prepare for such encounters by being aware
that they exist and by taking appropriate steps to reduce the obstacles.
Furthermore, if private industry reminds agency officials that external factors
such as economic and political forces should not be relied upon in determining
the outcome of a particular marketing application, then perhaps the agency will
concern itself more with the scientific and medical impact a new drug provides,
rather than on hypothetical political effects.
3. Establishing an International Drug Dossier. An international registration
dossier is a comprehensive scientific document used to obtain worldwide
licensing approval of a drug by diverse health authorities. 89 Its purpose is to
condense the various regulatory requirements concerning chemical regulation
into a standardized set of objective criteria in order to establish a uniform
acceptance of research data.' 90 A comprehensive, cohesive, well-referenced and
professionally written dossier can assure expeditious handling by registration
authorities and, more likely than not, an early approval of the license applica-
tion.'
The international dossier concept has been discussed by experts in
drug development, and the EEC has move partly toward that goal.
Its equivalent in the field of chemical regulation has been vigorously
debated by chemical experts who are trying to make the U.S.
chemical approval system more like that of the EEC system. Some
form of "passport" for U.S. chemical developments may be seen
within ten years. In the drug field, we are very likely to see evolution
of a de facto, if not a de jure, uniformity of acceptance for research
data, controls and chemistry sections, bio-equivalence testing
methods, and manufacturing quality controls. 192
187. O'Reilly, supra note 11, at 137.
188. Id
189. Buday, The Mechanics of Assembling an International Drug Dossier, 17 DRUG INFO. J. 133
(1983). The factors to take into consideration of assembling such a dossier are planning and
scheduling of the dossier; creating, organizing and formatting; typing; copying and collating; working
with extramural suppliers and services; and shipping the document to the field. Id.
190. O'Reilly, supra note 11, at 134.
191. Buday, supra note 189, at 138.
192. O'Reilly, supra note 11, at 134.
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However, even though the concept of an international drug dossier has
received some attention in recent years,' 93 implementing the dossier concept
has not achieved any considerable international success. A company wishing to
establish such a dossier must undertake an enormous amount of time and money
to research the necessary requirements before beginning such a dossier.' 9,
However, since the CPMP has employed the Notice to Applicants procedure,' 9'
implementation of an international dossier system can be based on the European
system by expanding the procedure to international proportions. If the CPMP
system can be applied to achieve a dossier which is appropriate and satisfactory
for all concerned, then the international dossier plan can succeed.
In summary, increasing the methods of communication by using more MOUs,
CROs, and assessment reports, by reducing economic and political forces, and
by establishing an international drug dossier, the obstacles associated with the
international acceptance of foreign clinical data can be reduced. For this to
work, however, regulatory agencies need to first recognize that concerted action
must be taken on an international scale. Ultimately, more international
meetings between these regulatory agencies are needed with the topic of foreign
clinical data on the agenda. Also, these channels of communication, once
opened, must remain continually open if the increased acceptability of foreign
clinical data is to make any impact at all upon the increased availability of
pharmaceutical drugs.
CONCLUSION
As stated in the Introduction, Beth and Bill are just two examples of patients
who do not have access to helpful drugs which are available in other countries.
Because there are thousands of patients like Beth and Bill, drug regulatory
agencies must reduce the barriers which inhibit the free flow of pharmaceutical
drugs internationally. The drug lag is just one of the unfortunate effects that
results from agencies who reject foreign clinical data. And, if the drug lag
continues, so will our health care problems because patients will be unable to
obtain innovative new drugs.
The problems associated with the international acceptance of foreign clinical
data have become readily apparent to national drug regulatory agencies,
particularly the FDA and CPMP. As a result of this awareness, these agencies
have adopted standards in determining when foreign clinical data will be
acceptable. However, these agencies face problems applying a consistent
interpretation to these standards. This prevents international pharmaceutical
manufacturers from anticipating what studies will be acceptable. To achieve a
consistent interpretation of an application, national barriers and economic and
political forces must be reduced.
193. See O'Reilly, supra note 11, at 134; Buday, supra note 189, at 133.
194. See generally Buday, supra note 189, at 133.
195. See supra notes 123-30 and accompanying text.
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These barriers can be reduced by increasing methods of communication
through the use of MOUs, CROs, and by requiring assessment reports to be
used on an international scale. Also, establishing an international drug dossier
system can hasten the approval process if the European Notice to Applicants
procedure is implemented on an international scale. If such steps can be made
in the near future, patients like Beth and Bill may be able to obtain the drugs
which could save their lives.
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